InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,246.40
(
0.37%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.99
(
0.95%
)
Bitcoin
61,352.88
(
-0.74%
)
Post# of 252359
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cooldrinkh2o

Send PM Follow Ignore
Followers 0
Posts 113
Boards Moderated 0
Alias Born 05/28/2005

cooldrinkh2o

Re: masterlongevity post# 169933

Wednesday, 11/13/2013 3:17:45 PM

Wednesday, November 13, 2013 3:17:45 PM

Post# of 252359
It's hard to compare. The ibrutinib patient pop failed chop-Rituxan (with or without Rituxan maintenance) and potentially velcade (50 of the 115 pts). OR was 68%, CR - 21%, PFS - 13.9 mo

http://www.nejm.org/doi/full/10.1056/NEJMoa1306220


A better comparison might be velcade in a similar (slightly less heavily pre-treated pop)--TTP -6.7 mo

http://www.ncbi.nlm.nih.gov/pubmed/19074748
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up